Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800327 | 0.83 | EPHX2 (0.46) | MRGPRX1TACR1EPHX2PPARGSLC6A2 | |
| SCHEMBL30482017 | 0.83 | EPHX2 (0.46) | MRGPRX1TACR1EPHX2PPARGSLC6A2 | |
| SCHEMBL13077648 | 0.83 | MEN1 (0.48) | HDAC4HDAC6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18893127 | 0.79 | EPHX2 (0.44) | MRGPRX1EPHX2PPARG | |
| SCHEMBL3679075 | 0.76 | SMN1; SMN2 (0.57) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL3678237 | 0.76 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2LMNATACR1 | |
| SCHEMBL3678235 | 0.76 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2LMNATACR1 | |
| SCHEMBL3679074 | 0.76 | SMN1; SMN2 (0.57) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL2168291 | 0.75 | CASR (0.67) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL3746949 | 0.75 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2LMNATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093650-A1 | RESOLUTION OF ALPHA-(PHENOXY)PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES | METABOLEX, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093650-A1 | RESOLUTION OF ALPHA-(PHENOXY)PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES | METABOLEX, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7432394-B2 | Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines | METABOLEX, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432394-B2 | Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines | METABOLEX, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2007038277-A2 | RESOLUTION OF ALPHA-(PHENOXY) PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES | METABOLEX, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070073082-A1 | Reacting enantiomers of 4-chloro- alpha -(3-trifluoromethylphenoxy)phenylacetic acid with (S)-(-)-1-(2-naphthyl)ethylamine to form an ammonium salt; separating the naphthylalkylammonium salt of the first enantiomer from the mixture; separating naphthylalkylamine | METABOLEX, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070073082-A1 | Reacting enantiomers of 4-chloro- alpha -(3-trifluoromethylphenoxy)phenylacetic acid with (S)-(-)-1-(2-naphthyl)ethylamine to form an ammonium salt; separating the naphthylalkylammonium salt of the first enantiomer from the mixture; separating naphthylalkylamine | METABOLEX, INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073082-A1 | Reacting enantiomers of 4-chloro- alpha -(3-trifluoromethylphenoxy)phenylacetic acid with (S)-(-)-1-(2-naphthyl)ethylamine to form an ammonium salt; separating the naphthylalkylammonium salt of the first enantiomer from the mixture; separating naphthylalkylamine | NAT1, SLC43A1, AGTR1 | HDAC4 2126/4885HDAC6 1625/4885MEN1 3887/4885 |
| US-20090093650-A1 | RESOLUTION OF ALPHA-(PHENOXY)PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES | ADRA1A, NAT1, PAOX | HDAC4 1414/4885HDAC6 1181/4885MEN1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.